Valeo Financial Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $281K | Buy |
+1,301
| New | +$249K | 0.01% | 641 |
|
|
2026
Q1 | – | Sell |
-1,197
| Closed | -$211K | – | 774 |
|
|
2025
Q4 | $211K | Buy |
+1,197
| New | +$196K | ﹤0.01% | 742 |
|
|
2025
Q3 | – | Sell |
-1,794
| Closed | -$225K | – | 838 |
|
|
2025
Q2 | $225K | Buy |
+1,794
| New | +$224K | 0.01% | 671 |
|
|
2024
Q4 | – | Sell |
-1,563
| Closed | -$303K | – | 745 |
|
|
2024
Q3 | $303K | Sell |
1,563
-423
| -21% | -$88.5K | 0.01% | 524 |
|
|
2024
Q2 | $460K | Buy |
1,986
+574
| +41% | +$125K | 0.01% | 412 |
|
|
2024
Q1 | $285K | Buy |
1,412
+489
| +53% | +$115K | 0.01% | 517 |
|
|
2023
Q4 | $239K | Sell |
923
-320
| -26% | -$78.6K | 0.01% | 558 |
|
|
2023
Q3 | $319K | Buy |
1,243
+106
| +9% | +$28.4K | 0.01% | 442 |
|
|
2023
Q2 | $324K | Sell |
1,137
-29
| -2% | -$8.63K | 0.01% | 417 |
|
|
2023
Q1 | $324K | Buy |
1,166
+128
| +12% | +$35.4K | 0.02% | 422 |
|
|
2022
Q4 | $287K | Sell |
1,038
-217
| -17% | -$61.3K | 0.02% | 396 |
|
|
2022
Q3 | $335K | Buy |
1,255
+55
| +5% | +$11.7K | 0.02% | 317 |
|
|
2022
Q2 | $245K | Sell |
1,200
-199
| -14% | -$40.7K | 0.02% | 399 |
|
|
2022
Q1 | $295K | Sell |
1,399
-10
| -0.7% | -$2.17K | 0.02% | 450 |
|
|
2021
Q4 | $338K | Buy |
1,409
+180
| +15% | +$46.3K | 0.02% | 389 |
|
|
2021
Q3 | $348K | Buy |
1,229
+22
| +2% | +$7.21K | 0.02% | 368 |
|
|
2021
Q2 | $418K | Sell |
1,207
-48
| -4% | -$14.5K | 0.03% | 296 |
|
|
2021
Q1 | $351K | Buy |
1,255
+13
| +1% | +$3.51K | 0.02% | 329 |
|
|
2020
Q4 | $304K | Sell |
1,242
-1,134
| -48% | -$293K | 0.02% | 332 |
|
|
2020
Q3 | $674K | Sell |
2,376
-42
| -2% | -$11.7K | 0.06% | 159 |
|
|
2020
Q2 | $647K | Buy |
2,418
+363
| +18% | +$109K | 0.06% | 159 |
|
|
2020
Q1 | $658K | Sell |
2,055
-39
| -2% | -$11.8K | 0.07% | 154 |
|
|
2019
Q4 | $621K | Buy |
2,094
+1,388
| +197% | +$385K | 0.06% | 167 |
|
|
2019
Q3 | $164K | Sell |
706
-200
| -22% | -$46.6K | 0.02% | 334 |
|
|
2019
Q2 | $212K | Buy |
906
+101
| +13% | +$23.3K | 0.02% | 276 |
|
|
2019
Q1 | $190K | Buy |
805
+227
| +39% | +$71.5K | 0.02% | 288 |
|
|
2018
Q4 | $174K | Sell |
578
-203
| -26% | -$64.8K | 0.02% | 278 |
|
|
2018
Q3 | $238K | Buy |
781
+58
| +8% | +$20K | 0.03% | 253 |
|
|
2018
Q2 | $246K | Sell |
723
-143
| -17% | -$40.2K | 0.03% | 253 |
|
|
2018
Q1 | $237K | Buy |
866
+169
| +24% | +$52.5K | 0.04% | 234 |
|
|
2017
Q4 | $222K | Buy |
697
+136
| +24% | +$43.6K | 0.04% | 232 |
|
|
2017
Q3 | $176K | Buy |
+561
| New | +$166K | 0.04% | 212 |
|
Other funds holding BIIB
Valeo Financial Advisors's BIIB Position: Q2 2026 in Review
Valeo Financial Advisors opened a new position in Biogen (BIIB) in Q2 2026: 1,301 shares worth $281K. The stake represents 0.01% of the portfolio and ranks #641 among its holdings. This is a return to the name: Valeo Financial Advisors previously reported a position in BIIB as recently as Q4 2025.
Valeo Financial Advisors first reported a position in BIIB in Q3 2017 and has held it in 32 quarters since. The position peaked at $674K in Q3 2020. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Valeo Financial Advisors held 1,301 shares of Biogen worth $281K as of Q2 2026.
- Biogen was a new Valeo Financial Advisors position in Q2 2026.
- Biogen made up 0.01% of Valeo Financial Advisors's portfolio in Q2 2026, its #641 holding.
- Valeo Financial Advisors first reported a position in Biogen in Q3 2017 and has held it in 32 quarters since.
- Valeo Financial Advisors's Biogen position peaked at $674K in Q3 2020.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.